-
Automation-Only Is NOT AI: Beware, HEOR Colleagues
Sep 9, 2025, 16:22 PM -
The Development of the Multicriteria Decision Analysis in Specialized Burn Care: The Methodological Process
Sep 9, 2025, 16:22 PM -
What Are the Impacts of the Absence of Health Economic Evaluations for Drugs Granted an ASMR IV Rating by the French National Authority of Health (HAS)? An Analysis of Medicines Assessed Between May 2022 and May 2024
Sep 9, 2025, 16:22 PM -
From Diagnosis to Treatment: Evaluating Timeliness and Treatment Patterns in Czech Pancreatic Cancer Patients
Sep 9, 2025, 16:22 PM -
Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France
Sep 9, 2025, 16:22 PM -
Evaluating the Validity of Immunotherapy in Retreatment and Rechallenge Strategies for Oncology Patients
Sep 9, 2025, 16:22 PM -
The Challenges of Evaluating Individualized Therapies in Health Technology Assessment: A Thematic Review
Sep 9, 2025, 16:22 PM -
Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Obstruction in Italian Healthcare Service
Sep 9, 2025, 16:22 PM -
Real-World Evidence in Action: Assessing Drug-Drug Interactions to Drive Value-Based Decisions
Sep 9, 2025, 16:22 PM -
Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource
Sep 9, 2025, 16:22 PM -
Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis
Sep 9, 2025, 16:22 PM -
Quantifying the Fiscal Value of Prevention Programs for Depression
Sep 9, 2025, 16:22 PM -
Factors Associated With the Publication of Real-World Evidence Studies in Lung Cancer by Journal Impact Factor
Sep 9, 2025, 16:22 PM -
Operational and Economic Impact of CLL Treatment Regimens: Insights From a Multidisciplinary Study in Portugal
Sep 9, 2025, 16:22 PM -
HTA Conflicts in Europe: Agreeing to Disagree?
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Sep 9, 2025, 16:22 PM -
Mapping Access Pathways for New Medicines in Finland: A Real-World Review of HTA and Reimbursement Decisions
Sep 9, 2025, 16:22 PM -
Real-World Adherence to Nonhormonal Therapies for Menopause-Related Vasomotor Symptoms: A Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Productivity Losses Due to Ill Health Among Adults Aged 50 and Older in Greece
Sep 9, 2025, 16:22 PM -
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data
Sep 9, 2025, 16:22 PM
